How often, on average, do you forget to take your daily meds? For me, it’s about twice a week. And that’s for something as low stakes as a vitamin D supplement; it’s not the end of the world if I’m a little deficient. But when it comes to HIV prevention, missing a dose of your prescribed daily prevention pills could …
Read More »
Summary What is already known about this topic? HIV preexposure prophylaxis (PrEP) reduces HIV incidence; however, adherence to available PrEP regimens is suboptimal. In June 2025, FDA approved injectable lenacapavir (LEN) administered every 6 months as HIV PrEP, based on results from two randomized controlled trials (RCTs) that reported LEN efficacy at reducing HIV infection as 100% among females and …
Read More »
PEPFAR Release September 4, 2025 Today, the U.S. Department of State announced a market-shaping initiative by the President’s Emergency Plan for AIDS Relief (PEPFAR) to bring U.S.-based Gilead Sciences’ breakthrough drug lenacapavir to market in high-burden HIV countries. The initiative – which will promote global scale in production and distribution of the medication and catalyze further global investment – has …
Read More »
The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response. The guidelines are being issued at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, …
Read More »